Sun Pharma's Deuruxolitinib Shows Improved Hair Satisfaction in Severe Alopecia Areata Patients

Sun Pharmaceutical Industries Limited (Sun Pharma) will present clinical efficacy and safety data of its oral selective inhibitor of Janus Kinases (JAK) JAK1 and JAK2, LEQSELVI™ (deuruxolitinib) 8 mg tablets, at the 33% European Academy of Dermatology and Venereology (EADV) Congress. The data presented in the podium presentation found a greater proportion (95%) of patients taking deuruxolitinib 8 mg twice a day showed improvement in their hair satisfaction scores, compared to baseline over the 24-week period. The company will also share results in two additional posters for deuruxolitinib, which showed clinically meaningful improvement in anxiety and depression among patients taking deuruxolitinib to treat their severe AA as well as dose optimization for deuruxolitinib at 8 mg. Additionally, 12 poster presentations will underscore the clinical efficacy and safety of ILUMYA® (tildrakizumab) in moderate-to-severe plaque psoriasis.